Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Merkel cell carcinoma occurring in a black woman: a case report

  • Selma Kadiri1Email author,
  • Abdellah Aissa1,
  • Soufiane Berhili1,
  • Mouna Khmou2,
  • Sanaa Elmajjaoui1,
  • Tayeb Kebdani1,
  • Basma El Khannoussi2,
  • Hanan Elkacemi1 and
  • Noureddine Benjaafar1
Journal of Medical Case Reports201711:25

DOI: 10.1186/s13256-016-1189-8

Received: 5 January 2016

Accepted: 27 December 2016

Published: 31 January 2017

Abstract

Background

Merkel cell carcinoma is a rare, very aggressive neuroectodermal tumor of the skin. It is typically located on sun-exposed skin and frequently found in white men aged between 70 and 80 years.

Case presentation

We report a case of a 58-year-old black woman diagnosed with Merkel cell carcinoma of the posterior face of the right elbow. She had biopsy excision and was lost to follow-up. Four months later, she presented with recurrent disease on the inferior third of the right arm with three ipsilateral axillary lymph node metastases. Amputation of the right arm and ipsilateral axillary lymph node dissection were performed, followed by adjuvant radiotherapy. Six months later, the patient died as a result of respiratory failure caused by lung metastasis. To the best of our knowledge, no specific studies have been done comparing the course and the characteristics of Merkel cell carcinoma in white and black populations, and no similar case has been reported in the literature.

Conclusions

The Merkel cell carcinoma is very rare in black people. As described elsewhere in the literature, our patient had a poor outcome despite radical management. To date, to the best of our knowledge, there has been no comparison of the prognosis of this tumor in white and black populations.

Keywords

Merkel cell carcinoma Dark skin Elbow Radiotherapy

Background

Merkel cell carcinoma (MCC) is a rare and very aggressive neuroendocrine tumor of the skin [1]. It affects adults with light skin types in the seventh decade of life and has a high rate of local recurrence and regional lymph node metastasis [2]. MCC was first described in 1972 by Toker [3]. It seems to arise from the basal layer of the epidermis where specific cells—the Merkel cells—are located [4]. This hypothesis is controversial, and recent observations suggest that these tumors originate from an immature totipotential dermal stem cell that acquires neuroendocrine features during malignant transformation [5].

We report a rare case of an epidemiological presentation of MCC occurring in the right elbow of a black woman. We also try to show through this case if there are differences in prognosis between MCC occurring in white and black people.

Case presentation

A 58-year-old African black woman with a medical history of diabetes presented to our institute with a rapidly growing skin lesion that was initially a small, round, painless nodule on the posterior face of the right elbow. In a physical examination at the time of admission, a 50 × 30-mm purple lesion with an irregular surface on the posterior face of the right elbow and extending to the forearm was found. No ipsilateral axillary lymph nodes were found. The patient had stage II disease. A biopsy excision was performed. The pathological examination showed a proliferation of round, small cells (Fig. 1a, b). An immunohistochemical study using specific staining techniques confirmed the diagnosis of MCC and, more specifically, cytokeratin 20 (CK20) expression, which is often evident as a paranuclear globule (Fig. 2); synaptophysin (Fig. 3); CD99; neuron-specific enolase; and negativity of the melanocytic and muscular markers. The patient was lost to follow-up and consulted us 4 months later. The physical examination done at that time revealed a large inflammatory lesion of 100 × 50 mm on the third inferior side of the right arm with three ipsilateral axillary lymph nodes. A magnetic resonance imaging (MRI) scan of the right arm showed a process of the soft parts of 103 × 63 × 50 mm with three metastatic ipsilateral axillary lymph nodes (Fig. 4).
Fig. 1

a Cutaneous neuroendocrine carcinoma. Typical low-power view of a small blue-cell tumor (hematoxylin and eosin stain, original magnification ×40). b Microphotograph showing pale-staining, small, round cell proliferation containing tiny nucleoli (hematoxylin and eosin stain, original magnification ×40)

Fig. 2

High-power view of the tumor showing strong expression of cytokeratin 20 (original magnification ×40)

Fig. 3

High-power view of the tumor showing strong expression of synaptophysin (original magnification ×40)

Fig. 4

Contrast-enhanced, T1-weighted axial magnetic resonance imaging scan showing the process of the soft parts on the right arm

A biopsy of one of the axillary lymph nodes confirmed the diagnosis of MCC. Computed tomography (CT) of the chest, abdomen, and pelvis showed no distant metastasis. The treatment planning consisted of surgical amputation of the right arm with ipsilateral axillary lymph node dissection. A histopathologic examination revealed negative surgical margins. The margins were found to be microscopically uninvolved by carcinoma, with the closest margin at 4 mm (deep margin). Of 31 excised lymph nodes, 13 that were metastatic with capsular rupture were found.

The patient was referred to our radiation therapy department. At that admission, the examination revealed a clean amputation stump and no axillary lymphadenopathy, but the patient had a fixed mass in the right axilla. A CT scan showed a process in the right axillary region extending to the right subscapularis fossa (Fig. 5). No surgical treatment was possible. A decision was made to perform radiation therapy of the right axillary and subscapularis regions. The total dose was 66 Gy with a conventional fractionation of 2 Gy per fraction in 33 sessions, 5 days per week, in the right axillary and subscapular areas in two oblique fields: anterior right and posterior left fields. The patient had grade 2 radiodermatitis as the only acute toxicity of radiotherapy.
Fig. 5

Computed tomography slice showing a mass in the right axillary and subscapularis regions

Six months later, the patient presented with dyspnea caused by lung metastasis, and she died 1 month afterward as a result of respiratory failure.

Discussion

MCCs are rare tumors of the skin. According to National Cancer Institute Surveillance, Epidemiology, and End Results Program data, the estimated annual incidence in 2006 was 0.6 per 100,000 persons [6]. In Australia and New Zealand, higher incidence rates are reported [7]. These tumors occur mostly in the white population (94%) [8, 9]. Males develop MCC more often than females, with incidence rates of 0.41 and 0.18 cases per 100,000 person-years, respectively [6]. MCC is typically seen in the elderly, with mean ages at diagnosis of 74 years for men and 76 years for women [6]. Our patient was a 58-year-old woman.

MCCs often occur on sun-exposed regions of the skin [8, 9]. The etiology is largely uncertain, though there is some evidence that ultraviolet radiation and immune system depression are important risk factors. More recently, some studies have shown the role of the Merkel cell polyomavirus (MCV) group in the development of this tumor [8, 10]. MCV has been isolated in up to 80% of the MCC tissue analyzed [11].

MCC presents as a painless, purple lump on the skin, sometimes ulcerated. It can be multifocal [1]. The head and neck are the most common primary sites (48%), followed by the upper limbs (19%), lower limbs (16%), and trunk (11%) [12]. Most patients (73%) present with localized disease (stages I–II); 23% have regional disease (stage III), and 4% have stage IV metastatic disease [12].

The histological presentation of MCC is small, round, blue-cell tumors and need to be distinguished from lymphoma, melanoma, sarcoma, and metastatic skin deposits from other neuroendocrine carcinomas, in particular small cell lung carcinoma. Immunohistochemical study characteristics of neuroendocrine carcinoma of the skin is low-molecular-weight (CAM 5.2) keratin, and more specifically CK20 expression, which is often evident by paranuclear immunostaining [13]. CK7 is characteristically negative in MCC and may be positive in small cell lung carcinoma [13]. Neuroendocrine markers (neurofilament protein, chromogranin, and synaptophysin) are frequently expressed in MCC tumors [14]. The tumor cells are negative for leukocyte common antigen, HMB-45, Melan-A, desmin, and myogenin. A protocol of examination of specimens from patients with MCC has been developed to assist pathologists in providing clinically relevant information [15, 16].

Common sites of MCC metastasis include distant lymph nodes (60%), distant skin (30%), lung (23%), central nervous system (60%), and bone (15%) [12]. CT and MRI scans are obtained to evaluate MCC and for treatment planning, but there is no accepted imaging algorithm [8]. Recently, however, some studies have shown that fluorodeoxyglucose-positron emission tomography is a highly sensitive modality for MCC evaluation before and after treatment [5].

The standard treatment of the primary tumor remains surgical. Removal by wide local excision is typical, with some surgeons also using Mohs micrographic surgery to ensure adequate clear margins at excision [17]. Lymph node dissection and primary nodal radiotherapy are options for treating clinically node-negative disease. For clinically palpable regional disease, lymph node dissection is recommended with consideration of adjuvant radiation therapy. In recent studies, the role of sentinel lymph node biopsy in guiding adjuvant treatment has been established [18]. Adjuvant radiotherapy doses ranged from 45 to 66 Gy, depending on the techniques used and the presence of microscopic or gross disease after surgery. The role of neoadjuvant and adjuvant chemotherapy is not clear and should be analyzed in more studies [8].

Prognostic factors are primary tumor size up to 2 cm and a high mitotic index, which may contribute to a higher risk of locoregional recurrence [19, 20]. An increasing number of metastatic nodes is associated with significantly worse overall survival [8, 21]. Five-year survival is 57% for localized disease, 39% for regional disease, and 18% for metastatic disease [19, 22]. Recurrence rates of MCC are high, with most occurring within 2 years (often earlier) and increasing with higher stage at presentation [23, 24].

In our patient, the tumor size was up to 2 cm, and she presented with locoregional recurrence very early (4 months). She died after lung metastasis only 6 months after the end of treatment. To the best of our knowledge, there are no studies in the literature in which researchers analyzed the impact of skin color and geographic or ethnic origin on the prognosis of MCC. As in the other nonmelanoma skin cancers (basal and squamous cell carcinoma), routine skin scanning and dermatological examination should be done in the elderly population to provide early diagnosis and therapeutic care [25].

Conclusions

MCC presents rarely in dark-skinned people, which suggests a protective role of their skin pigmentation. As seen in our patient and as reported in the literature, MCC has a poor outcome. However, more studies should be done to analyze the difference in prognosis between light- and dark-skinned populations. The high rate of local and distant recurrence of MCC despite radical management and a multidisciplinary approach deserve more research on the role of systemic treatment.

Abbreviations

CK: 

Cytokeratin

CT: 

Computed tomography

MCC: 

Merkel cell carcinoma

MCV: 

Merkel cell polyomavirus

MRI: 

Magnetic resonance imaging

Declarations

Acknowledgements

All the authors are thankful for provision of the necessary facilities for the preparation of the manuscript.

Funding

Special thanks are due to the Faculty of Medicine and Pharmacy of Rabat, the source of funding for all authors.

Availability of data and materials

Not applicable.

Authors’ contributions

SK examined the patient, began radiotherapy, participated in the sequence alignment, and drafted the manuscript. BEK and MK carried out histological and immunohistochemical studies of the tumor. AA and SB participated in the sequence alignment. SE, TK, and HE helped to draft the manuscript. NB coordinated between departments and also revised and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Radiotherapy, National Institute of Oncology
(2)
Department of Cytopathology, National Institute of Oncology

References

  1. Prieto I, Pérez de la Fuente T, Medina S, Castelo B, Sobrino B, Fortes JR, et al. Merkel cell carcinoma: an algorithm for multidisciplinary management and decision-making. Crit Rev Oncol Hematol. 2016;98:170–9.View ArticlePubMedGoogle Scholar
  2. Tothill R, Estall V, Rischin D. Merkel cell carcinoma: emerging biology, current approaches and future directions. Am Soc Clin Oncol Educ Book. 2015:e519–26.Google Scholar
  3. Toker C. Trabecular carcinoma of the skin. Arch Dermatol. 1972;105:107–10.View ArticlePubMedGoogle Scholar
  4. Ratner D, Nelson BR, Brown MD, Johnson TM. Merkel cell carcinoma. J Am Acad Dermatol. 1993;29:143–56.View ArticlePubMedGoogle Scholar
  5. Prieto I, Pardo J, Olivera J, Medina MS, Jover R, Perez AM. Merkel cell carcinoma from 2008 to 2012: reaching a new level of understanding. Cancer Treat Rev. 2013;39:421–9.View ArticleGoogle Scholar
  6. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2010;37:20–7.View ArticlePubMedGoogle Scholar
  7. Girschik J, Thorn K, Beer TW, Heenan PJ, Fritschi L. Merkel cell carcinoma in Western Australia: a population-based study of incidence and survival. Br J Dermatol. 2011;165:1051–7.View ArticlePubMedGoogle Scholar
  8. Prewett SL, Ajithkumar T. Merkel cell carcinoma: current management and controversies. Clin Oncol (R Coll Radiol). 2015;27:436–44.View ArticleGoogle Scholar
  9. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol. 2005;89:1–4.View ArticlePubMedGoogle Scholar
  10. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–100.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Spurgeon ME, Lambert PF. Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology. 2013;435:118–30.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI, Beenken SW. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol. 2001;8:204–8.View ArticlePubMedGoogle Scholar
  13. Bichakjian CK, Lowe L, Lao CD, Sandler HM, Bradford CR, Johnson TM, et al. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer. 2007;110:1–12.View ArticlePubMedGoogle Scholar
  14. Bobos M, Hytiroglou P, Kostopoulos I, Karkavelas G, Papadimitriou CS. Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung. Am J Dermatopathol. 2006;28:99–104.View ArticlePubMedGoogle Scholar
  15. Rao P, Balzer BL, Lemos BD, Liegeois NJ, McNiff JM, Nghiem P, et al. Protocol for the examination of specimens from patients with Merkel cell carcinoma of the skin. Washington, DC: College of American Pathologists (CAP); 1996–2010. http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/skinmerkelcell-12protocol.pdf. Accessed 13 Sept 2012.
  16. Calonje E, Brenn T, Lazar A, McKee PH. Tumors of the surface epithelium. In: McKee’s pathology of the skin: with clinical correlations, vol. 2. 4th ed. Philadelphia: Saunders Elsevier; 2012. p. 1076–149.View ArticleGoogle Scholar
  17. Gonzalez RJ, Padhya TA, Cherpelis BS, Prince MD, Aya-Ay ML, Sondak VK, et al. The surgical management of primary and metastatic Merkel cell carcinoma. Curr Probl Cancer. 2010;34:77–96.View ArticlePubMedGoogle Scholar
  18. Guihard S, Noël G. Merkel cell carcinoma, role of radiotherapy and literature review [in French]. Cancer Radiother. 2009;13:47–54.View ArticlePubMedGoogle Scholar
  19. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63:751–61.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Tai PT, Yu E, Tonita J, Gilchrist J. Merkel cell carcinoma of the skin. J Cutan Med Surg. 2000;4:186–95.PubMedGoogle Scholar
  21. Howle JR, Hughes TM, Gebski V, Veness MJ. Merkel cell carcinoma: an Australian perspective and the importance of addressing the regional lymph nodes in clinically node negative patients. J Am Acad Dermatol. 2012;67:33–40.View ArticlePubMedGoogle Scholar
  22. Sarnaik AA, Lien MH, Nghiem P, Bichakjian CK. Clinical recognition, diagnosis, and staging of Merkel cell carcinoma, and the role of the multidisciplinary management team. Curr Probl Cancer. 2010;34:38–46.View ArticlePubMedGoogle Scholar
  23. Fields RC, Busam KJ, Chou JF, Panageas KS, Pulitzer MP, Allen PJ, et al. Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma. Cancer. 2012;118:3311–20.View ArticlePubMedGoogle Scholar
  24. Salvador Alonso R, Lahbabi I, Ben Hassel M, Boisselier P, Chaari N, Lesimple T, et al. Merkel cell carcinoma: outcome and role of radiotherapy [in French]. Cancer Radiother. 2008;12:352–9.View ArticlePubMedGoogle Scholar
  25. Koyuncuer A. Histopathological evaluation of non-melanoma skin cancer. World J Surg Oncol. 2014;12:159. doi:10.1186/1477-7819-12-159.

Copyright

© The Author(s). 2017

Advertisement